Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL7521557 | 0.93 | MAPK1 (0.42) | MAPK1ALDH1A1TSHR | |
| Cyclohexane SCHEMBL4991233 | 0.89 | MAPK1 (0.40) | MAPK1ALDH1A1TSHR | |
| Ethyl Chloride SCHEMBL10588167 | 0.88 | MAPK1 (0.44) | MAPK1ALDH1A1TSHR | |
| Hexane SCHEMBL9455882 | 0.84 | TSHR (0.43) | MAPK1ALDH1A1TSHR | |
| Acetone SCHEMBL11413386 | 0.84 | TSHR (0.41) | MAPK1ALDH1A1TSHR | |
| Ether SCHEMBL15135184 | 0.84 | MAPK1 (0.36) | MAPK1 | |
| Chloromethane SCHEMBL11103401 | 0.82 | — | — | |
| SCHEMBL7240952 | 0.82 | — | — | |
| SCHEMBL1296 | 0.82 | — | — | |
| SCHEMBL10940023 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160246-A | Process for recovering valsartan from valsartan mother liquor | 江苏新瑞药业有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-106905398-B | Synthetic method of sofosbuvir | ZHEJIANG A & F UNIVERSITY (CN) | 2019-12-10 | — | — | CN | claimed |
| CN-106905398-A | A kind of synthetic method of Suo Feibuwei | 浙江农林大学 | 2017-06-30 | — | — | CN | claimed |
| CN-102399253-B | A kind of preparation method of Tan Bolong acetic ester | BEIJING KEYIFENG BIOTECH DEVELOPMENT CO., LTD. (CN) | 2015-12-09 | — | — | CN | claimed |
| CN-102351881-B | Stable levofloxacin hydrochloride compound | TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO LTD | 2014-04-09 | — | — | CN | claimed |
| CN-103242356-A | Preparation method of bortezomib intermediate isobutaneboronic acid | SUZHOU HEALTH COLLEGE | 2013-08-14 | — | — | CN | claimed |
| CN-102229601-B | Hexahydro-1-(5-isoquinoline sulfonyl)-1 (H)-1, 4- diazepine hydrochloride amorphous compound | TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO LTD | 2013-07-03 | — | — | CN | claimed |
| CN-102399253-A | Preparation method of trenbolone acetate | BEIJING KEYIFENG BIOTECH DEV CO LTD | 2012-04-04 | — | — | CN | claimed |
| CN-102351881-A | Stable levofloxacin hydrochloride compound | TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO LTD | 2012-02-15 | — | — | CN | claimed |
| CN-102010381-B | Improved preparation method of valsartan | SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd. (CN) | 2012-02-08 | — | — | CN | claimed |
| CN-102229601-A | Hexahydro-1-(5-isoquinoline sulfonyl)-1 (H)-1, 4- diazepine hydrochloride amorphous compound | TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO LTD | 2011-11-02 | — | — | CN | claimed |
| CN-102010381-A | Improved preparation method of valsartan | SHANDONG XINSHIDAI PHARMACEUTICAL CO LTD | 2011-04-13 | — | — | CN | claimed |
| US-20090286989-A1 | Process for High Purity Anastrozole | SHILPA MEDICARE LTD. (IN) | 2009-11-19 | — | — | US | claimed |
| EP-1994014-A1 | IMPROVED PROCESS FOR HIGH PURITY ANASTROZOLE | Shilpa Medicare Limited (IN) | 2008-11-26 | — | — | EP | claimed |
| WO-2007105231-A1 | IMPROVED PROCESS FOR HIGH PURITY ANASTROZOLE | SHILPA MEDICARE LTD. (IN) | 2007-09-20 | — | — | WO | claimed |
| US-6433164-B1 | — | — | None | — | — | US | disclosed |
| CN-117999257-A | Bicyclic heterocyclic derivatives having virus proliferation inhibitory activity and pharmaceutical compositions containing the same | 盐野义制药株式会社 | 2024-05-07 | — | — | CN | disclosed |
| US-3944541-A | 22-Cyano-24-norcholanes | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
| US-3944577-A | Novel pregnane-21-oic acid derivatives | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-03-16 | — | — | US | disclosed |
| US-3932388-A | STEROIDS, GLUCOCORTICOID ACITIVITY | SCHERING CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286989-A1 | Process for High Purity Anastrozole | CYP19A1, CYP3A5, AURKC | MAPK1 764/4885ALDH1A1 1933/4885TSHR 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.